Flavonoids as dopaminergic neuromodulators

Molecular Nutrition and Food Research

Volumn 60, Issue 3, 2016, Pages 495-501

  Meireles, Manuela ^a   Moura, Eduardo ^a   Vieira Coelho, Maria Augusta ^a   Santos Buelga, Celestino ^b   Gonzalez Manzano, Susana ^b   Dueñas, Montserrat ^b   Mateus, Nuno ^c   Faria, Ana ^a,c   Calhau, Conceição ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Dopamine transporter; Dopaminergic cells; Flavonoids; Methyl 4 phenylpyridinuim; Organic cation transport

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CATION; DOPAMINE; DOPAMINE TRANSPORTER; ENZYME INHIBITOR; FLAVONOID; PIPERAZINE DERIVATIVE; VANOXERINE;

ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYLPYRIDINIUM; CATIONS; CELL LINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; NEURONS; NEUROTRANSMITTER AGENTS; PIPERAZINES; SIGNAL TRANSDUCTION;

EID: 84959466412     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500557     Document Type: Article

References (40)

1. Faria, A., Mateus, N., de Freitas, V., Calhau, C., Modulation., of MPP+ uptake by procyanidins in Caco-2 cells: involvement of oxidation/reduction reactions. FEBS Lett. 2006, 580, 155-160.
2. Monteiro, R., Calhau, C., Martel, F., Faria, A. et al., Modulation of MPP+ uptake by tea and some of its components in Caco-2 cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 2005, 372, 147-152.
3. Martel, F., Monteiro, R., Calhau, C., Effect of polyphenols on the intestinal and placental transport of some bioactive compounds. Nutr. Res. Rev. 2010, 23, 47-64.
4. Meireles, M., Martel, F., Araujo, J., Santos-Buelga, C. et al. Characterization and modulation of glucose uptake in a human blood-brain barrier model. J. Memb Biol. 2013, 246, 669-677.
5. Youdim, K. A., Spencer, J. P., Schroeter, H., Rice-Evans, C., Dietary flavonoids as potential neuroprotectants. Biol. Chem. 2002, 383, 503-519.
6. Kesse-Guyot, E., Fezeu, L., Andreeva, V. A., Touvier, M. et al., Total and specific polyphenol intakes in midlife are associated with cognitive function measured 13 years later. J. Nutr. 2012, 142, 76-83.
7. Letenneur, L., Proust-Lima, C., Le Gouge, A., Dartigues, J. F., Barberger-Gateau, P., Flavonoid intake and cognitive decline over a 10-year period. Am. J. Epidemiol. 2007, 165, 1364-1371.
8. Williams, R. J., Spencer, J. P., Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic. Biol. Med. 2012, 52, 35-45.
9. Koepsell, H., Lips, K., Volk, C., Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Res. 2007, 24, 1227-1251.
10. Vaughan, R. A., Foster, J. D., Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacological Sci. 2013, 34, 489-496.
11. Gonzalez-Manzano, S., Gonzalez-Paramas, A., Santos-Buelga, C., Duenas, M., Preparation and characterization of catechin sulfates, glucuronides, and methylethers with metabolic interest. J. Agric. Food Chem. 2009, 57, 1231-1238.
12. Dueñas, M., Mingo-Chornet, H., Pérez-Alonso, J. J., Di Paola-Naranjo, R. et al., Preparation of quercetin glucuronides and characterization by HPLC-DAD-ESI/MS. Eur. Food Res. Technol. 2008, 227, 1069-1076.
13. Presgraves, S. P., Ahmed, T., Borwege, S., Joyce, J. N., Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotoxicity Res. 2004, 5, 579-598.
14. Xie, H. R., Hu, L. S., Li, G. Y., SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin. Med. J. (Engl.) 2010, 123, 1086-1092.
15. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
16. Collatz, M. B., Rudel, R., Brinkmeier, H., Intracellular calcium chelator BAPTA protects cells against toxic calcium overload but also alters physiological calcium responses. Cell Calcium. 1997, 21, 453-459.
17. Sampaio-Maia, B., Soares-da-Silva, P., Ca2+/calmodulin mediated pathways regulate the uptake of L-DOPA in mouse neuroblastoma neuro 2A cells. Life Sci. 2000, 67, 3209-3220.
18. Newton, R., Cambridge, L., Hart, L. A., Stevens, D. A. et al., The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br. J. Pharmacol. 2000, 130, 1353-1361.
19. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592-5595.
20. Bain, J., Plater, L., Elliott, M., Shpiro, N. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408, 297-315.
21. Mogami, H., Lloyd Mills, C., Gallacher, D. V., Phospholipase C inhibitor, U73122, releases intracellular Ca2+, potentiates Ins(1, 4, 5)P3-mediated Ca2+ release and directly activates ion channels in mouse pancreatic acinar cells. Biochem. J. 1997, 324, 645-651.
22. Beecher, G. R., Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr. 2003, 133, 3248S-3254S.
23. Hollman, P. C., Katan M. B., Dietary flavonoids: intake, health effects and bioavailability. Food Chem. Toxicol. 1999, 37, 937-942.
24. Kaur, C., Kapoor, H. C., Antioxidants in fruits and vegetables - the millennium's health. Int. J. Food Sci. Technol. 2001, 36, 703-725.
25. Van Duyn, M. A., Pivonka, E., Overview of the health benefits of fruit and vegetable consumption for the dietetics professional: selected literature. J. Am. Diet Assoc. 2000, 100, 1511-1521.
26. Andrade, J. P., Assuncao, M., Protective effects of chronic green tea consumption on Age-related neurodegeneration. Curr. Pharm. Des. 2012, 18, 4-14.
27. Andres-Lacueva, C., Shukitt-Hale, B., Galli, R. L., Jauregui, O. et al., Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. Nutr. Neurosci. 2005, 8, 111-120.
28. Rice-Evans, C. A., Miller, N. J., Paganga, G., Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 1996, 20, 933-956.
29. Duenas, M., Gonzalez-Manzano, S., Gonzalez-Paramas, A., Santos-Buelga, C., Antioxidant evaluation of O-methylated metabolites of catechin, epicatechin and quercetin. J. Pharm. Biomed. Anal. 2010, 51, 443-449.
30. Faria, A., Meireles, M., Fernandes, I., Santos-Buelga, C. et al. Flavonoid metabolites transport across a human BBB model. Food Chem. 2014, 149, 190-196.
31. Nehlig, A., The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br. J. Clin. Pharmacol. 2013, 75, 716-727.
32. Okushio, K., Suzuki, M., Matsumoto, N., Nanjo, F., Hara, Y., Identification of (-)-epicatechin metabolites and their metabolic fate in the rat. Drug Metab. Disposition 1999, 27, 309-316.
33. Hendrich, A. B., Flavonoid-membrane interactions: possible consequences for biological effects of some polyphenolic compounds. Acta Pharmacologica Sinica 2006, 27, 27-40.
34. Lee, E. H., Meissner, G., Kim, D. H., Effects of quercetin on single Ca(2+) release channel behavior of skeletal muscle. Biophys. J. 2002, 82, 1266-1277.
35. Faria, A., Monteiro, R., Pestana, D., Freitas, V. et al. Intestinal oxidative state can alter nutrient and drug bioavailability. Oxidative Med. Cell. Longevity 2009, 2, 322-327.
36. Pifl, C., Giros, B., Caron, M. G., Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 1993, 13, 4246-4253.
37. Bezard, E., Gross, C. E., Fournier, M. C., Dovero, S. et al., Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 1999, 155, 268-273.
38. Storch, A., Ludolph, A. C., Schwarz, J., Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural. Transm. 2004, 111, 1267-1286.
39. Deik, A., Saunders-Pullman, R., Luciano, M. S., Substance abuse and movement disorders: complex interactions and comorbidities. Curr. Drug Abuse Rev. 2012, 5, 243-53.
40. Sekine, Y., Iyo, M., Ouchi, Y., Matsunaga, T. et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry 2001, 158, 1206-1214.